Mycobacterium setense isolated from a cat with atypical mycobacterial panniculitis

Zusammenfassung

Bei einer Katze wurde eine atypische mykobakterielle Pannikulitis diagnostiziert. Mittels 16S-rRNA-Gen-Sequenzanalyse ließ sich Mycobacterium setense, ein grampositives stäbchenförmiges säurefestes Bakterium der Mycobacterium fortuitum-Gruppe nachweisen, das zuvor nie bei einem erkrankten Tier isoliert werden konnte. Initial wurden Resistenzen gegen Doxycyclin und Clarithromycin festgestellt und während der Behandlung mit Pradofloxacin entwickelte sich zudem eine Resistenz gegen Fluorchinolone, bedingt durch eine Mutation im Gyrasegen gyrA (S90W-Austausch). Trotz einer langfristigen antimikrobiellen Behandlung über 33 Monate wurde keine vollständige Heilung erzielt. Bei einer atypischen mykobakteriellen Pannikulitis ist die Speziesbestimmung mit Resistenztest die Grundlage für eine adäquate Antibiose.

Abstract

Atypical mycobacterial panniculitis was diagnosed in a cat. Mycobacterium setense was identified as causative agent by 16 S rRNA gene sequence analysis. This a gram-positive rod-shaped acid-fast bacterium belonging to Mycobacterium fortuitum group was never reported before in diseased animals. Resistance to doxycycline and clarithromycin was detected. During treatment with pradofloxacin, additional resistance to fluoroquinolones developed which was due to a mutation in the gyrase gene gyrA (S90W exchange). Despite of antimicrobial treatment for 33 months the patient did not fully recover. Species identification and susceptibility testing for choosing adequate antimicrobial treatment is recommended in cases of feline mycobacterial panniculitis.

Schlüsselwörter

Antimikrobielle Resistenz - schnell wachsende Mykobakterien - Mycobacterium fortuitum-Gruppe - 16S-rRNA-Gen - gyrA

Key words

Antimicrobial resistance - rapidly growing mycobacteria - Mycobacterium fortuitum group - 16 S rRNA gene - gyrA

• References

• 1 Malik R, Wigney DI, Dawson D. et al. Infection of the subcutis and skin of cats with rapidly growing mycobacteria: a review of microbiological and clinical findings. J Feline Med Surg 2000; 2 (01) 35-48
• 2 Greene CE. Infectious Diseases of the Dog and Cat. 4th ed. Philadelphia: Saunders; 2013
• 3 Vishkautsan P, Reagan KL, Keel MK. et al. Mycobacterial panniculitis caused by Mycobacterium thermoresistibile in a cat. JFMS Open Rep 2016; 2 (02) 2055116916672786
• 4 Gunn-Moore DA. Feline mycobacterial infections. Vet J 2014; 201 (02) 230-238
• 5 Forbes BA, Hall GS, Miller MB. et al. Practice Guidelines for Clinical Microbiology Laboratories: Mycobacteria. Clin Microbiol Rev 2018; 31 (02)
• 6 Gupta RS, Lo B, Son J. Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera. Front Microbiol 2018; 9: 67
• 7 Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev 2014; 27 (04) 727-752
• 8 Lamy B, Marchandin H, Hamitouche K. et al. Mycobacterium setense sp. nov., a Mycobacterium fortuitum-group organism isolated from a patient with soft tissue infection and osteitis. Int J Syst Evol Microbiol 2008; 58 Pt 2 486-490
• 9 Davari M, Irandoost M, Sakhaee F. et al. Genetic Diversity and Prevalence of Nontuberculous Mycobacteria Isolated from Clinical Samples in Tehran, Iran. Microb Drug Resist 2019; 25 (02) 264-270
• 10 Shojaei H, Hashemi A, Heidarieh P. et al. First report on isolation and molecular characterization of clinical Mycobacterium setense isolates in Asia. Jpn J Infect Dis 2011; 64 (03) 234-236
• 11 Toro A, Adekambi T, Cheynet F. et al. Mycobacterium setense infection in humans. Emerg Infect Dis 2008; 14 (08) 1330-1332
• 12 Kothari S, Antoine S, Naqvi H. et al. First Report On Mycobacterium Setense-Associated Lower Respiratory Tract Infection in U.S.A. Am J Respir Crit Care Med 2014; 189: A1736
• 13 van der Werf MJ, Ködmön C, Katalinić-Janković V. et al. Inventory study of non-tuberculous mycobacteria in the European Union. BMC Infect Dis 2014; 14: 62
• 14 Gelatt KN, van der Woerdt A, Ketring KL. et al. Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol 2001; 4 (02) 99-106
• 15 Sieber-Ruckstuhl NS, Sessions JK, Sanchez S. et al. Long-term cure of disseminated Mycobacterium avium infection in a cat. Vet Rec 2007; 160 (04) 131-132
• 16 Govendir M, Hansen T, Kimble B. et al. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. Vet Microbiol 2011; 147 1–2 113-118
• 17 Plumb DC. Plumb’s veterinary drug handbook. 7th ed. Ames, Iowa: Wiley-Blackwell; 2011
• 18 Koch SN, Torres SMF, Plumb DC. Canine and Feline Dermatology Drug Handbook. Ames Iowa: Wiley-Blackwell; 2012
• 19 Lloret A, Hartmann K, Pennisi MG. et al. Mycobacterioses in cats: ABCD guidelines on prevention and management. J Feline Med Surg 2013; 15 (07) 591-597
• 20 Nol P, Rhyan JC, Robbe-Austerman S. et al. The potential for transmission of BCG from orally vaccinated white-tailed deer (Odocoileus virginianus) to cattle (Bos taurus) through a contaminated environment: experimental findings. PLoS ONE 2013; 8 (04) e60257
• 21 Palmer MV, Thacker TC, Waters WR. et al. Persistence of Mycobacterium bovis bacillus Calmette-Guérin (BCG) Danish in white-tailed deer (Odocoileus virginianus) vaccinated with a lipid-formulated oral vaccine. Transbound Emerg Dis 2014; 61 (03) 266-272
• 22 Kušar D, Zajc U, Jenčič V. et al. Mycobacteria in aquarium fish: results of a 3-year survey indicate caution required in handling pet-shop fish. J Fish Dis 2017; 40 (06) 773-784
• 23 Messias A, Gekeler F, Wegener A. et al. Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. Doc Ophthalmol 2008; 116 (03) 177-191
• 24 Lees P. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. J Vet Pharmacol Ther 2013; 36 (03) 209-221
• 25 Govendir M, Norris JM, Hansen T. et al. Susceptibility of rapidly growing mycobacteria and Nocardia isolates from cats and dogs to pradofloxacin. Vet Microbiol 2011; 153 3–4 240-245
• 26 Dong Y, Zhao X, Domagala J. et al. Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43 (07) 1756-1758
• 27 Takiff HE, Salazar L, Guerrero C. et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38 (04) 773-780
• 28 Guillemin I, Cambau E, Jarlier V. Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones. Antimicrob Agents Chemother 1995; 39 (09) 2145-2149
• 29 Kocagöz T, Hackbarth CJ, Unsal I. et al. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40 (08) 1768-1774
• 30 Yoshida H, Bogaki M, Nakamura M. et al. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother 1990; 34 (06) 1271-1272
• 31 Guillemin I, Jarlier V, Cambau E. Correlation between Quinolone Susceptibility Patterns and Sequences in the A and B Subunits of DNA Gyrase in Mycobacteria. Antimicrob Agents Chemother 1998; 42 (08) 2084-2088
• 32 Avalos E, Catanzaro D, Catanzaro A. et al. Frequency and Geographic Distribution of gyrA and gyrB Mutations Associated With Fluoroquinolone Resistance in Clinical Mycobacterium Tuberculosis Isolates: A Systematic Review. PLoS ONE 2015; 10 (03)
• 33 Uppal RP, Verma SP, Verma V. et al. Comparative pharmacokinetics of amikacin following a single intramuscular or subcutaneous administration in goats (Capra hircus). Vet Res 1997; 28 (06) 565-570
• 34 European Medicines Agency AMEG 2018 – Categorisation of antibiotics EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP). Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals. https://www.ema.europa.eu/en/documents/report/categorisation-antibiotics-euro​pean-union-answer-request-european-commission-updating-scientific​_en.pdf Stand: 30.04.2020
• 35 Guardabassi L, Damborg P, Stamm I. et al. Diagnostic microbiology in veterinary dermatology: present and future. Vet Dermatol 2017; 28 (01) 146-e30
• 36 Hnot ML, Cole LK, Lorch G. et al. Evaluation of canine-specific minocycline and doxycycline susceptibility breakpoints for meticillin-resistant Staphylococcus pseudintermedius isolates from dogs. Vet Dermatol 2015; 26 (05) 334-338 e70-1
• 37 Pang H, Li G, Wan L. et al. In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents. Int J Clin Exp Med 2015; 8 (09) 15423-15431
• 38 Weese JS, Giguère S, Guardabassi L. et al. ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. J Vet Intern Med 2015; 29 (02) 487-498